Strong Consumables Sales Help Qiagen Post 20-Percent Revenue Gain in Q3 | GenomeWeb
This article has been updated from a previous version, which incorrectly stated that 7 percent of Qiagen's third-quarter revenue came from Genaco Biomedical, instead of from acquisitions.
 
NEW YORK (GenomeWeb News) — Qiagen today said third-quarter revenues increased 20 percent as R&D spending rose 29 percent and profit increased 10 percent.
 
Total receipts for the three months ended Sept. 30 increased to $117.9 million from $98.6 million year over year, beating its guidance of $116 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.